Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
| ▸ | TNK1 | Q13470 | 14/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 11/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249596 | 0.86 | PARP1 (1.00) | PARP1TNK1TNK2 | |
| SCHEMBL18314106 | 0.86 | PARP1 (1.00) | PARP1TNK1TNK2 | |
| Nesuparib SCHEMBL30093972 | 0.85 | PARP1 (1.00) | PARP1TNK1TNK2 | |
| Nesuparib SCHEMBL29411324 | 0.85 | PARP1 (1.00) | PARP1TNK1TNK2 | |
| Nesuparib SCHEMBL18314125 | 0.85 | PARP1 (1.00) | PARP1TNK1TNK2 | |
| SCHEMBL18314105 | 0.84 | PARP1 (1.00) | PARP1TNK1TNK2 | |
| SCHEMBL18314192 | 0.84 | PARP1 (1.00) | PARP1TNK1TNK2 | |
| SCHEMBL18314236 | 0.83 | PARP1 (1.00) | PARP1TNK1TNK2 | |
| SCHEMBL18314126 | 0.83 | PARP1 (1.00) | PARP1TNK1TNK2 | |
| SCHEMBL20249594 | 0.82 | PARP1 (1.00) | PARP1TNK1TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464919-B2 | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2019-11-05 | — | — | US | disclosed |
| US-20180162834-A1 | Tricyclic Derivative Compound, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | ONCONIC THERAPEUTICS INC. (KR) | 2018-06-14 | — | — | US | disclosed |
| US-20180162834-A1 | Tricyclic Derivative Compound, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | ONCONIC THERAPEUTICS INC. (KR) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162834-A1 | Tricyclic Derivative Compound, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | TNKS, TNKS2, PARP1 | PARP1 3/4885TNK1 26/4885TNK2 53/4885 |
| US-10464919-B2 | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | TNKS, TNKS2, PARP1 | PARP1 3/4885TNK1 26/4885TNK2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.